Method of treating prostate cancer with GnRH antagonist
AssigneeFerring B.V.
InventorsEgbert A. van der Meulen, Laszlo Balazs Tanko
Life of this patent
Estimating the term…
Abstract
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Claims11
A method of treating prostate cancer in a subject, comprising:
- selecting a subject that has prostate cancer and a history of at least one cardiovascular event;
- and
- administering degarelix to the subject, wherein administering degarelix to the subject comprises administering to the patient an initial dose of degarelix of 240 mg given as two injections of 120 mg each, and administering to the patient a maintenance dose of degarelix of 80 mg given as one injection, wherein the maintenance dose is administered approximately every 28 days after the previous dose of degarelix for a duration treatment,
- wherein administering degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Dependencies are inferred from the claim text.